Celltrion Healthcare Reports Q1 Operating Profit of 45 Billion KRW, Up 43% Year-on-Year

[Asia Economy Reporter Lee Gwan-ju] Celltrion Healthcare announced on the 13th that its consolidated operating profit for the first quarter of this year reached 45 billion KRW, a 43% increase compared to the same period last year. During the same period, sales amounted to 415.7 billion KRW, up 17%, and net profit was 43.6 billion KRW, up 38% respectively.

The company explained that sales of the blood cancer treatment biosimilar 'Truxima' (generic name Rituximab) increased in the North American region, and prescriptions for the subcutaneous injection form autoimmune disease treatment 'Remsima SC' (generic name Infliximab), sold in Europe, steadily grew, contributing to the performance growth.

They also announced plans to strengthen their portfolio through new product launches. Celltrion Healthcare plans to launch 'CT-P16' (generic name Bevacizumab), an Avastin biosimilar for metastatic colorectal and breast cancer treatment, in Europe by the end of this year.

CT-P16's Phase 3 clinical trial results demonstrating equivalence in efficacy to the original drug were announced last month at the American Association for Cancer Research (AACR). Approval applications were completed in Europe and the United States in October last year, and the approval process is currently underway.

A Celltrion Healthcare official stated, “Despite the first quarter being an off-season, we achieved meaningful results as prescriptions of existing products expanded steadily across the globe, including the highly profitable North American region.”

This content was produced with the assistance of AI translation services.